Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

What Contributes to the Appearance of Dual MPNs?

Am J Hematol; 2017 Jun; Kandarpa, Wu, et al

Publish date:: July 23, 2017

Hematopoietic cells from patients with myeloproliferative neoplasms (MPNs) harbor multiple genetic aberrations that can contribute to clonal dominance, according to a recent study.

Investigators looked at neoplastic cells from patients with dual MPNs using next-generation sequencing to see if they could characterize the underlying genetic events that might contribute to the appearance of more than one MPN. Among the results:

Most patients with two MPNs harbored mutations in genes known to contribute to clonal hematopoiesis through altered epigenetic regulation such as TET2, ASXL1/2, SRSF2, and IDH2 at varying frequencies.
Some patients also harbored oncogenic mutations in N/KRAS, TP53, BRAF, EZH2, and GNAS at low frequencies, reflective of clonal evolution.

Citation:

Kandarpa M, Wu Y, Robinson D, Burke P, Chinnaiyan A, Talpaz M. Clinical characteristics and whole exome/transcriptome sequencing of coexisting chronic myeloid leukemia and myelofibrosis. Am J Hematol. 2017;92(6):555-561. doi:10.1002/ajh.24728.

This Week's Must Reads

Consider potential cognitive complications prior to androgen deprivation therapy,

Diabetes raises risk of prostate cancer mortality in obese men,

Salivation inhibition fails to reduce radioiodine toxicity in prostate cancer,

Highest positive surgical margin predicts poor survival after prostatectomy,

Young minority men are underinformed about prostate cancer screening,

Must Reads in Hematologic Malignancies

Long-term ibrutinib data in older patients, Barr PM et al. Haematologica. 2018;103(9):1502-10

Prognostic Score System for Patients with PMF, J Clin Oncol; ePub 2017 Dec 9; Gugliemelli, et al

These Patients Are More Apt to Be Depressed, Ann Hematol; ePub 2017 Dec 7; Shreders, et al

Survival Length Shortest in These Patients with MF, Eur J Haematol; ePub 2017 Dec 11; Masarova, et al

The Value of Ruxolitinib Before and After AlloSCT, Blood; ePub 2017 Dec 7; Poulose, Malysz, et al